• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Amylyx Pharmaceuticals Inc.

    4/23/26 7:02:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMLX alert in real time by email
    DEFA14A 1 amlx-defa14a-2026-additi.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934 (Amendment No. )

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

     

    Preliminary Proxy Statement

     

     

     

    ☐

     

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

     

     

    ☐

     

    Definitive Proxy Statement

     

     

     

    ☒

     

    Definitive Additional Materials

     

     

     

    ☐

     

    Soliciting Material under §240.14a-12

     

    AMYLYX PHARMACEUTICALS, INC.

    (Name of registrant as specified in its charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

     

    No fee required

     

     

     

    ☐

     

    Fee paid previously with preliminary materials

     

     

     

    ☐

     

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     


     

    img171810760_0.jpg

     

    Online Go to www.envisionreports.com/AMLX or scan the QR code — login details are located in the shaded bar below. Stockholder Meeting Notice Important Notice Regarding the Availability of Proxy Materials for the Amylyx Pharmaceuticals, Inc. Stockholder Meeting to be Held on Thursday, June 4, 2026. Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholder meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2026 proxy statement and annual report to stockholders are available at: www.envisionreports.com/AMLX Easy Online Access — View your proxy materials and vote. Step 1: Go to www.envisionreports.com/AMLX. Step 2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Obtaining a Copy of the Proxy Materials – If you want to receive a paper or email copy of the proxy materials, you must request one. If you do not request it, you will not otherwise receive a paper or email copy. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side of this form on or before May 25, 2026 to facilitate timely delivery. 2NOT 049Y8A

     


     

     

    img171810760_1.jpg

     

    Stockholder Meeting Notice The 2026 Annual Meeting of Stockholders of Amylyx Pharmaceuticals, Inc. will be held on Thursday, June 4, 2026, at 9:00 a.m. ET, virtually via the internet at meetnow.global/M75QLG2. To access the virtual meeting, you must have the information that is printed in the shaded bar located on the reverse side of this form. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommends a vote FOR all the nominees listed, and FOR Proposals 2 and 3: 1. Election of Directors: To elect the following persons to our board of directors, each to serve as a Class II director until the 2029 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director’s earlier death, resignation or removal: 01 -George Mclean Milne Jr., Ph.D. 02 -Paul Fonteyne 2. To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. 3. To approve, on a non-binding, advisory basis, the compensation of our named executive officers. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.envisionreports.com/AMLX. Click Cast Your Vote or Request Materials. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to [email protected] with “Proxy Materials Amylyx Pharmaceuticals, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side of this form, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by May 25, 2026.

     


    Get the next $AMLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMLX

    DatePrice TargetRatingAnalyst
    3/3/2026$21.00Buy
    Stifel
    7/10/2025$10.00Buy
    Goldman
    6/24/2025$17.00Buy
    Guggenheim
    6/17/2025$12.00Buy
    Citigroup
    5/30/2025Buy
    TD Cowen
    4/7/2025$7.00Neutral → Outperform
    Mizuho
    11/18/2024$3.00 → $11.00Neutral → Outperform
    Robert W. Baird
    10/23/2024$4.20 → $10.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $AMLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Firestone Karen bought $100,845 worth of shares (8,100 units at $12.45), increasing direct ownership by 15% to 63,100 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    12/23/25 8:48:33 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Zeiher Bernhardt G bought $37,005 worth of shares (10,000 units at $3.70) (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    3/24/25 4:15:37 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Frates James M bought $101,368 worth of shares (40,000 units at $2.53), increasing direct ownership by 21% to 233,464 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    9/16/24 5:30:37 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 29, 2022 - FDA Approves New Treatment Option for Patients with ALS

    For Immediate Release: September 29, 2022 The U.S. Food and Drug Administration today approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease.  “This approval provides another important treatment option for ALS, a life-threatening disease that currently has no cure,” said Billy Dunn, M.D., director of the Off

    9/29/22 5:02:14 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    September 2, 2022 - FDA Roundup: September 2, 2022

    For Immediate Release: September 02, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:   On Thursday, the FDA published the FDA Voices: “Using A Whole-Of-Governments Approach to Combating Illicit Health Products,” by Cathy Hermsen, Assistant Commissioner for Criminal Investigations and Ritu Nalubola, Director of the FDA’s Europe Office. Crimi

    9/2/22 1:46:13 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Amylyx Pharmaceuticals with a new price target

    Stifel initiated coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $21.00

    3/3/26 8:26:33 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Amylyx Pharmaceuticals with a new price target

    Goldman resumed coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $10.00

    7/10/25 8:47:27 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Amylyx Pharmaceuticals with a new price target

    Guggenheim initiated coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $17.00

    6/24/25 7:57:48 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

    Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference. The corporate presentation will take place on Wednesday, April 15, 2026, at 8:45 a.m. ET. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the event. About Amylyx Pharmaceuticals At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we

    4/8/26 9:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

    Last participant has been randomized and dosed in the LUCIDITY trial of avexitide; LUCIDITY enrolled a total of 78 participants Topline data readout on track; anticipated in Q3 2026 LUCIDITY is evaluating the FDA-agreed-upon primary outcome of reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that the last participant has been randomized and dosed in the pivotal Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist with U.S. Food and Drug Administration (FDA) Breakthrough Therapy De

    3/24/26 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with topline data anticipated in Q3 2026 Cash runway expected to fund operations through potential avexitide commercialization and into 2028 Management to host conference call and webcast today at 8:00 a.m. Eastern Time Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today reported financial and business results for the fourth quarter and full year ended December 31, 2025. "2025 was a year of meaningful advancement for Amylyx's pivotal avexitide program in post-bariatric hypoglycemia, as well as

    3/3/26 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Amylyx Pharmaceuticals Inc.

    DEFA14A - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)

    4/23/26 7:02:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Amylyx Pharmaceuticals Inc.

    DEF 14A - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)

    4/23/26 7:01:02 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Amylyx Pharmaceuticals Inc.

    SCHEDULE 13G/A - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    3/26/26 3:41:51 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Frates James M was granted 95,990 shares, increasing direct ownership by 58% to 261,628 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    3/9/26 4:00:07 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Mazzariello Gina was granted 74,660 shares, increasing direct ownership by 56% to 209,090 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    3/9/26 4:00:08 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Co-Chief Executive Officer Cohen Joshua B was granted 248,865 shares, increasing direct ownership by 7% to 3,583,548 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    3/9/26 4:00:10 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Leadership Updates

    Live Leadership Updates

    View All

    Amylyx Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 9, 2024 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 08, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursui

    4/8/24 6:24:09 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer

    - Dr. Bedrosian brings to Amylyx nearly 30 years of leadership in clinical research, development, and advancing pipeline programs into commercialized global products including as CMO at Ultragenyx, Alexion, and ARIAD Pharmaceuticals Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the appointment of Camille L. Bedrosian, MD, as Chief Medical Officer ("CMO"). In this role, Dr. Bedrosian will lead global functions in medical affairs, regulatory, safety and pharmacovigilance, biometrics, clinical development, and clinical operations. Dr. Bedrosian brings nearly 30 years of experience addressing unmet medical needs for people with rare and serious disease

    11/28/23 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union

    Amylyx will seek re-examination of its Conditional Marketing Authorisation Application Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the application for conditional marketing authorisation of AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine [also known as taurursodiol]), under the trade name ALBRIOZA®, for the treatment of adults with amyotrophic lateral sclerosis (ALS) in the European Union (EU). Today's update follows the Company's May 2023 announcement that the CHMP was trending toward a negative opinion.

    6/23/23 8:14:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Financials

    Live finance-specific insights

    View All

    Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with topline data anticipated in Q3 2026 Cash runway expected to fund operations through potential avexitide commercialization and into 2028 Management to host conference call and webcast today at 8:00 a.m. Eastern Time Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today reported financial and business results for the fourth quarter and full year ended December 31, 2025. "2025 was a year of meaningful advancement for Amylyx's pivotal avexitide program in post-bariatric hypoglycemia, as well as

    3/3/26 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

    Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026. Amylyx's senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. To access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.c

    2/24/26 9:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

    - AMX0114 was generally well-tolerated, with no treatment-related serious adverse events - Amylyx will proceed with opening enrollment of second cohort - Data are being presented at the 36th International Symposium on ALS/MND Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the presentation of early safety and tolerability data from its Phase 1 LUMINA trial of AMX0114 and results from ongoing work characterizing biomarkers of AMX0114 target engagement at the 36th International Symposium on ALS/MND (MNDA) held from December 5-7 in San Diego, California. AMX0114 was generally well-tolerated in LUMINA trial participants enrolled in cohort 1 (n=12), with

    12/5/25 9:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Amylyx Pharmaceuticals Inc.

    SC 13G/A - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    11/12/24 1:22:53 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Amylyx Pharmaceuticals Inc.

    SC 13G - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    11/4/24 10:56:42 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Amylyx Pharmaceuticals Inc.

    SC 13G - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    10/25/24 5:38:25 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care